Imaging Techniques for Treatment Evaluation for Metastatic Breast Cancer [Retrospectively Entered]

Project Summary Title and Description

Imaging Techniques for Treatment Evaluation for Metastatic Breast Cancer [Retrospectively Entered]
The purpose of this technical brief is to understand current utilization of metastatic breast imaging modalities for treatment evaluation in the United States, both in order to summarize the current state of the science and to inform future research on this topic.
Authors of Report
Methodology description
We worked with Key Informants, including clinicians, patient advocates, representatives from the device manufacturing industry, and a product purchaser. Additionally, we searched gray and published literature from 2003–2013. We qualitatively synthesized the information from the Key Informant interviews and the gray literature. From the published literature, we abstracted data on the types of imaging used to evaluate treatment of metastatic breast cancer.
Funding Source
Prepared by the Pacific Northwest Evidence-based Practice Center under Contract No. HHSA 290-2012-00014-I, Agency for Healthcare Research and Quality. AHRQ Publication No. 14-EHC044-EF, available at: March 2015.

Key Questions

1. Key Question 1
2. Key Question 1
3. Key Question 1
4. Key Question 1
5. Key Question 1
6. Key Question 1
7. Key Question 1

Associated Extraction Forms

Associated Studies (each link opens a new tab)

Assessment of metastatic breast cancer response to chemoembolization with contrast agent enhanced and diffusion-weighted MR imaging.2007
Powerful prognostic stratification by 18Ffluorodeoxyglucose positron emission tomography in patients with metastatic breast cancer treated with high-dose chemotherapy.2006
18F-fluoromisonidazole PET/CT: a potential tool for predicting primary endocrine therapy resistance in breast cancer.2013
Monitoring early response to taxane therapy in advanced breast cancer with circulating tumor cells and (18)F 3´-deoxy-3´-fluorothymidine PET: a pilot study.2012
18F-3'Deoxy-3'-fluorothymidine positron emission tomography and breast cancer response to docetaxel.2011
Circulating tumor cells and 18Ffluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer.2009
Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET.2005
18F-FDG PET/CT predicts survival after radioembolization of hepatic metastases from breast cancer.2012
A prospective study of bone tumor response assessment in metastatic breast cancer.2013
Heterogeneity of metabolic response to systemic therapy in metastatic breast cancer patients.2010
Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3'-deoxy-3'-18Ffluorothymidine positron emission tomography.2007
Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer.2006
Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer.2011
Assessment of response to endocrine therapy using FDG PET/CT in metastatic breast cancer: a pilot study.2012
Usefulness of 3'-F-18fluoro-3'-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy.-- Not Found --
Serial 2-18F fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP).2007
Bone metastases in patients with metastatic breast cancer: morphologic and metabolic monitoring of response to systemic therapy with integrated PET/CT.2008

Downloadable Data Content

  • XLSX Project Data